KEYNOTE-010: Pembrolizumab versus docetaxel in advanced PD-L1-positive NSCLC - European Medical Journal

KEYNOTE-010: Pembrolizumab versus docetaxel in advanced PD-L1-positive NSCLC

Oncology

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD, from Lausanne University Hospital, Lausanne, Switzerland, discusses KEYNOTE-010, a phase 2/3 clinical trial that was designed to compare pembrolizumab, an anti-PD-1 antibody, against docetaxel, a commonly used chemotherapy, for patients with PD-L1-positive non-small cell lung cancer (NSCLC) after platinum-based therapy.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>